Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine

Molecular Diagnosis and Therapy

Volumn 14, Issue 3, 2010, Pages 185-190

  Ochsenreither, Sebastian ^a   Reinwald, Mark ^a   Thiel, Eckhard ^a   Burmeister, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ARMS; Diagnostic Tests; Genotyping; JAK2 kinase mutation V617f; melting point analysis; myeloproliferative disorder; Myeloproliferative disorders, diagnosis

Indexed keywords

DNA; JANUS KINASE 2;

ADULT; AGED; ARTICLE; BLOOD; BONE MARROW; CELL LINE; CONTROLLED STUDY; ERYTHROLEUKEMIA CELL; FEASIBILITY STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; MALE; MELTING POINT; PRIORITY JOURNAL; RELIABILITY;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; BIOLOGICAL ASSAY; CELL LINE, TUMOR; DIAGNOSTIC TESTS, ROUTINE; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; NUCLEIC ACID DENATURATION; YOUNG ADULT;

EID: 77954095446     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/bf03256372     Document Type: Article

References (35)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005 Apr 28; 434 (7037): 1144-1148 (Pubitemid 40663494)
2. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005 Apr 28; 352 (17): 1779-1790 (Pubitemid 40570926)
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005 Apr; 7 (4): 387-397
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005 Mar 19-25; 365 (9464): 1054-1061
5. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005 Jun 17; 280 (24): 22788-22792
6. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008 Jan; 22 (1): 14-22
7. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007 Aug 1; 110 (3): 840-846
8. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007 Sep; 21 (9): 1952-1959
9. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007 Dec 1; 110 (12): 4030-4036
10. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006 Sep 15; 108 (6): 2037-2040
11. Kroger N, Badbaran A, Holler E, et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007 Feb 1; 109 (3): 1316-1321
12. Steckel NK, Koldehoff M, Ditschkowski M, et al. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation 2007 Jun 15; 83 (11): 1518-1520
13. Palandri F, Ottaviani E, Salmi F, et al. JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. Leuk Lymphoma 2009 Feb; 50 (2): 247-253
14. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005 Dec 3; 366 (9501): 1945-1953
15. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and myelodysplastic syndromes. Blood 2005 Aug 15; 106 (4): 1207-1209
16. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005 Oct; 19 (10): 1847-1849
17. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005 Sep 15; 106 (6): 2162-2168
18. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005 Nov 15; 106 (10): 3370-3373
19. Antonioli E, Guglielmelli P, Poli G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008 Jan; 93 (1): 41-48
20. Olsen RJ, Tang Z, Farkas DH, et al. Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the Light- Cycler system. Arch Pathol Lab Med 2006 Jul; 130 (7): 997-1003
21. McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006 Jan; 20 (1): 168-171
22. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006 Feb; 20 (2): 350-353
23. Sutton BC, Allen RA, Zhao ZJ, et al. Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. Cancer Biomark 2007; 3 (6): 315-324
24. LayM, Mariappan R, Gotlib J, et al. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. J Mol Diagn 2006 Jul; 8 (3): 330-334
25. Murugesan G, Aboudola S, Szpurka H, et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. AmJ Clin Pathol 2006 Apr; 125 (4): 625-633
26. Martin P, Papayannopoulou T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science 1982; 216 (4551): 1233-1235
27. Quentmeier H, MacLeod R, Zaborski M, et al. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006; 20 (3): 471-476
28. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009 Sep 1; 115 (17): 3842-3847
29. Steensma DP. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006 Sep; 8 (4): 397-411; quiz 526
30. Lee JW, Soung YH, Kim SY, et al. JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas. Leuk Lymphoma 2006 Feb; 47 (2): 313-314
31. Vannucchi AM, Pancrazzi A, Bogani C, et al. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 2006 Jun; 20 (6): 1055-1060
32. Poodt J, Fijnheer R, Walsh IB, et al. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood. Hematol Oncol 2006 Dec; 24 (4): 227-233
33. Burmeister T, Schwartz S, Taubald A, et al. Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia. Haematologica 2007 Dec; 92 (12): 1699-1702
34. Lippert E, Girodon F, Hammond E, et al. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 2009 Jan; 94 (1): 38-45
35. Larsen TS, Pallisgaard N, Moller MB, et al. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis: impact on disease phenotype. Eur J Haematol 2007Dec; 79 (6): 508-515